Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/155760
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLee, Bei Shien_US
dc.contributor.authorPethe, Kevinen_US
dc.date.accessioned2022-03-17T08:47:24Z-
dc.date.available2022-03-17T08:47:24Z-
dc.date.issued2022-
dc.identifier.citationLee, B. S. & Pethe, K. (2022). Telacebec : an investigational antibacterial for the treatment of tuberculosis (TB). Expert Opinion On Investigational Drugs, 31(2), 139-144. https://dx.doi.org/10.1080/13543784.2022.2030309en_US
dc.identifier.issn1354-3784en_US
dc.identifier.urihttps://hdl.handle.net/10356/155760-
dc.description.abstractIntroduction: Tuberculosis is an infectious disease that affected more than 50 million people and killed 6.7 million patients in the past 5 years alone. Additionally, rising incidence of treatment resistance threatens the global effort to eradicate this disease. With limited options available, additional novel antibiotics are needed for the treatment of multidrug-resistant tuberculosis (MDR-TB). Telacebec is a first-in-class antibiotic that targets the pathogen’s energy metabolism. Areas covered: This paper provides an overview of the recent progress in the development and testing of telacebec. We discuss published clinical data and examine the design and setup of its clinical trials. We also offer insights on the therapeutic potential of telacebec and aspects of which should be evaluated in the future. Expert opinion: The first phase 2a trial showed a correlation between dosage and bacterial load in patient sputum, which should be confirmed using a direct measurement method such as colonyforming unit counting. Its clinical efficacy, favorable pharmacokinetic properties, low arrhythmogenic risk, and activity against MDR-TB strains make telacebec a suitable candidate for further development. Future clinical testing in combination with approved second-line drugs will reveal its full potential against MDR-TB. Considering recent preclinical studies, we also recommend initiating clinical trials for Buruli ulcer and leprosy.en_US
dc.description.sponsorshipNational Research Foundation (NRF)en_US
dc.language.isoenen_US
dc.relationNRF-NRFI06-2020- 0004en_US
dc.relationNRF-CRP18-2017-01en_US
dc.relation.ispartofExpert Opinion on Investigational Drugsen_US
dc.rightsThis is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Investigational Drugs on 26 Jan 2022, available online: http://www.tandfonline.com/10.1080/13543784.2022.2030309.en_US
dc.subjectScience::Biological sciences::Biochemistryen_US
dc.titleTelacebec : an investigational antibacterial for the treatment of tuberculosis (TB)en_US
dc.typeJournal Articleen
dc.contributor.schoolSchool of Biological Sciencesen_US
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en_US
dc.identifier.doi10.1080/13543784.2022.2030309-
dc.description.versionSubmitted/Accepted versionen_US
dc.identifier.issue2en_US
dc.identifier.volume31en_US
dc.identifier.spage139en_US
dc.identifier.epage144en_US
dc.subject.keywordsCytochrome bcc:aa3en_US
dc.subject.keywordsMycobacterium Tuberculosisen_US
dc.subject.keywordsOxidative Phosphorylationen_US
dc.subject.keywordsQ203en_US
dc.subject.keywordsRespirationen_US
dc.description.acknowledgementThis work was supported by the National Research Foundation (NRF) Singapore under its Investigatorship Program (grant NRF-NRFI06-2020- 0004) and NRF Competitive Research Programme (Project Award Number NRF-CRP18-2017-01).en_US
item.grantfulltextembargo_20230203-
item.fulltextWith Fulltext-
Appears in Collections:LKCMedicine Journal Articles
SBS Journal Articles
Files in This Item:
File Description SizeFormat 
EOID article FINAL.pdf
  Until 2023-02-03
325.52 kBAdobe PDFUnder embargo until Feb 03, 2023

Page view(s)

43
Updated on Jul 2, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.